Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196276 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL7926944 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL17923466 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL9431529 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL19287109 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL11575727 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL2094913 | 1.00 | — | — | |
| SCHEMBL11251398 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AALDH1A1 | |
| SCHEMBL994389 | 0.97 | — | — | |
| SCHEMBL481638 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402358-A2 | 2',3'-Didehydro-3'-deoxy-4'-ethynylothymidine derivatives for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and pharmaceutically acceptable forms of drugs | Instytut Biochemii I Biofizyki Pan (PL) | 2012-01-04 | — | — | EP | claimed |
| US-6602861-B1 | Acylated phospholipid drugs | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-08-05 | — | — | US | claimed |
| EP-0636134-B1 | NOVEL ACYLATED PHOSPHOLIPID DRUGS | RES CORP TECHNOLOGIES INC (US) | 1997-12-17 | — | — | EP | claimed |
| EP-0636134-A1 | NOVEL ACYLATED PHOSPHOLIPID DRUGS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-02-01 | — | — | EP | claimed |
| WO-1993021191-A1 | NOVEL ACYLATED PHOSPHOLIPID DRUGS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-10-28 | — | — | WO | claimed |
| CN-115806503-B | Selective histone deacetylase inhibitor and preparation method and application thereof | 中国海洋大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-115806503-A | Selective histone deacetylase inhibitor as well as preparation method and application thereof | 中国海洋大学 | 2023-03-17 | — | — | CN | disclosed |
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| EP-2402358-A3 | 2',3'-Didehydro-3'-deoxy-4'-ethynylothymidine derivatives for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and pharmaceutically acceptable forms of drugs | Instytut Biochemii I Biofizyki Pan (PL) | 2012-07-18 | — | — | EP | disclosed |
| EP-2402356-A2 | Modified 2',3'-dideoxynucleosides for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and the pharmaceutical agent containing these nucleosides | Instytut Biochemii I Biofizyki Pan (PL) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402358-A2 | 2',3'-Didehydro-3'-deoxy-4'-ethynylothymidine derivatives for treatment infections caused by human immunodeficiency virus (HIV) multidrug resistant strains, method of their synthesis and pharmaceutically acceptable forms of drugs | Instytut Biochemii I Biofizyki Pan (PL) | 2012-01-04 | — | — | EP | disclosed |
| US-20110027911-A1 | SOLUBILIZATION AND STUDY OF MEMBRANE PROTEINS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2009089430-A1 | SOLUBILIZATION AND STUDY OF MEMBRANE PROTEINS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-07-16 | — | — | WO | disclosed |
| US-6602861-B1 | Acylated phospholipid drugs | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-08-05 | — | — | US | disclosed |
| US-5846955-A | Acylated phospholipid drugs | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0636134-B1 | NOVEL ACYLATED PHOSPHOLIPID DRUGS | RES CORP TECHNOLOGIES INC (US) | 1997-12-17 | — | — | EP | disclosed |
| EP-0636134-A1 | NOVEL ACYLATED PHOSPHOLIPID DRUGS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993021191-A1 | NOVEL ACYLATED PHOSPHOLIPID DRUGS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | TSHR 2541/4885FAAH 189/4885TRPV1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.